Skip to content

Study · Observational study · n = 205 · 2013

9 results

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P

Minerva endocrinologica1 Mar 2013Cited by 26 (Europe PMC)

PMID23435446 (opens in a new tab)PepBankPUB-23435446
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, HbA1c was on average 1% lower than baseline at each visit.

    In plain wordsIn patients using liraglutide in routine care, HbA1c was about 1% lower than at the start at every visit.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus baseline
    Study

    n = 205

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    HbA1c reduction
    1%
    vs baseline

    Source sentences

    Summary
    On average, HbA1c levels were reduced of 1% vs. baseline at each visit
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, the size of the HbA1c reduction was inversely related to diabetes duration.

    In plain wordsIn patients using liraglutide, the HbA1c drop was smaller in people who had diabetes for longer.

    Peptide
    Liraglutide
    Outcome
    MixedHbA1c reduction by diabetes duration
    Study

    n = 205

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    but magnitude of reduction was inversely related to diabetes duration, i.e., to the preservation of beta-cell function.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, clinically relevant improvements of glycaemic control were sustained for two years in all subgroups.

    In plain wordsIn patients using liraglutide, better blood sugar control lasted two years in all groups checked.

    Peptide
    Liraglutide
    Outcome
    DecreaseDurability of glycaemic control over two years
    Study

    n = 205

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    However, clinically relevant improvements of glycaemic control were obtained and sustained during two years in all subgroups of patients, despite of classes of diabetes duration, BMI and antidiabetic therapeutic regimen.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  4. 04HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, durability of effectiveness on body weight was documented.

    In plain wordsIn patients using liraglutide, the effect on body weight lasted over the follow-up.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight durability
    Study

    n = 205

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Durability of effectiveness on body weight
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  5. 05HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, durability of effectiveness on waist circumference was documented.

    In plain wordsIn patients using liraglutide, the effect on waist size lasted over the follow-up.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference durability
    Study

    n = 205

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Durability of effectiveness on body weight and waist circumference was also documented.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  6. 06HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, liraglutide treatment was associated with a reduction of systolic blood pressure.

    In plain wordsIn patients using liraglutide, treatment was linked to lower systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 205

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment was also associated with a reduction of systolic blood pressure
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  7. 07HumanObservational studyEfficacy outcome

    In patients treated with liraglutide in routine care, liraglutide treatment was associated with improvement of the lipid profile.

    In plain wordsIn patients using liraglutide, treatment was linked to a better blood fat profile.

    Peptide
    Liraglutide
    Outcome
    MixedLipid profile
    Study

    n = 205

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    improvement of lipid profile.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  8. 08HumanObservational studySafety outcome

    In patients treated with liraglutide in routine care, side effects occurred in 20% in the first four months and decreased to 2% at 20 months.

    In plain wordsIn patients using liraglutide, side effects were seen in 20% early on and in 2% after 20 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseSide effects over time
    Study

    n = 205

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Side effect rate
    20%
    first four months
    Side effect rate
    2%
    20 months

    Source sentences

    Summary
    Side effects, that occurred in 20% of patients during the first four months of treatment, decreased at 2% at 20 months.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.
  9. 09HumanObservational studySafety outcome

    In patients treated with liraglutide in routine care, 16.1% of patients dropped out.

    In plain wordsIn patients using liraglutide in routine care, 16.1% stopped treatment.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment drop-out
    Study

    n = 205

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Drop-out rate
    16.1%
    treated patients

    Source sentences

    Summary
    The rate of drop-out was 16.1% of the patients treated.
    2 context sentences
    Summary · context
    One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up.
    Summary · context
    Overall, 205 patients were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.